Moderna Inc (MRNA) - Cash Flow Conversion Efficiency
Based on the latest financial reports, Moderna Inc (MRNA) has a cash flow conversion efficiency ratio of -0.085x as of March 2026. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow ($-630.00 Million) by net assets ($7.41 Billion). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations. See debt-free asset ratio of Moderna Inc to measure how much of total assets are equity-financed.
Moderna Inc - Cash Flow Conversion Efficiency Trend (2014–2025)
This chart illustrates how Moderna Inc's cash flow conversion efficiency has evolved over time, based on yearly financial data. Check Moderna Inc (MRNA) cash flow quality to evaluate the quality of earnings relative to operating cash generation.
Moderna Inc Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Moderna Inc ranked by their cash flow conversion efficiency.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Suzhou TFC Optical Communication Co Ltd
SHE:300394
|
0.123x |
|
Centrais Elétricas Brasileiras S.A. - Eletrobrás
F:L3XB
|
0.027x |
|
Baoshan Iron & Steel Co Ltd
SHG:600019
|
0.064x |
|
ASTELLAS PHARMA UNSP.ADR
F:YPHA
|
N/A |
|
AerCap Holdings N.V
F:R1D
|
0.078x |
|
Expeditors International of Washington, Inc.
NASDAQ:EXPD
|
0.088x |
|
Arca Continental S.A.B. de C.V
MX:AC
|
0.051x |
|
SNAM S.P.A. ADR 2
F:SNM0
|
N/A |
Annual Cash Flow Conversion Efficiency for Moderna Inc (2014–2025)
The table below shows the annual cash flow conversion efficiency of Moderna Inc from 2014 to 2025. For the full company profile with market capitalisation and key ratios, see Moderna Inc market capitalisation.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2025-12-31 | $8.65 Billion | $-1.87 Billion | -0.217x | +21.42% |
| 2024-12-31 | $10.90 Billion | $-3.00 Billion | -0.276x | -22.44% |
| 2023-12-31 | $13.85 Billion | $-3.12 Billion | -0.225x | -186.41% |
| 2022-12-31 | $19.12 Billion | $4.98 Billion | 0.260x | -72.95% |
| 2021-12-31 | $14.14 Billion | $13.62 Billion | 0.963x | +21.66% |
| 2020-12-31 | $2.56 Billion | $2.03 Billion | 0.791x | +302.59% |
| 2019-12-31 | $1.17 Billion | $-458.97 Million | -0.391x | -80.69% |
| 2018-12-31 | $1.53 Billion | $-330.87 Million | -0.216x | +59.21% |
| 2017-12-31 | $625.30 Million | $-331.48 Million | -0.530x | -768.75% |
| 2016-12-31 | $841.85 Million | $66.73 Million | 0.079x | +100.97% |
| 2015-12-31 | $90.19K | $-738.15K | -8.185x | -848.61% |
| 2014-12-31 | $-4.37 Million | $-4.78 Million | 1.093x | -- |
About Moderna Inc
Moderna, Inc., a biotechnology company, provides messenger RNA medicines in the United States, Europe, and internationally. The company's respiratory vaccines include spikevax, mNEXSPIKE, mRESVIA, COVID, RSV, seasonal influenza, combination, and pandemic influenza vaccine; latent vaccines comprise cytomegalovirus, epstein-barr virus, and human immunodeficiency virus vaccines; enteric viruses incl… Read more